<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407121</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0025</org_study_id>
    <nct_id>NCT00407121</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Inflammatory Neovascular Membranes</brief_title>
  <official_title>Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to
      intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and
      evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence
      Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous
      Choroidopathy and 1 patient with Multifocal Choroiditis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness by OCT</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Leakage in Fluorescein angiogram</measure>
  </primary_outcome>
  <condition>Vogt Koyanagi Harada Disease</condition>
  <condition>Serpiginous Choroiditis</condition>
  <condition>Multifocal Choroiditis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal Injection of Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnose

          -  Patient Consent

          -  Chronic stage of inflammation

        Exclusion Criteria:

          -  only eye

          -  age lower than 30 yo.

          -  Systemic condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Kon-Jara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LuzElena Concha-Del Rio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>December 1, 2006</last_update_submitted>
  <last_update_submitted_qc>December 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2006</last_update_posted>
  <keyword>Neovascular Membrane</keyword>
  <keyword>Uveitis</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroiditis</mesh_term>
    <mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

